92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 68-69

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Background/Significance

Sentinel lymph node (SLN) mapping is essential in the surgical management of early-stage breast cancer. Isosulfan blue is traditionally used but has drawbacks such as persistent skin staining and allergic reactions. Near-infrared fluorescence (NIRF) imaging with indocyanine green has emerged as a safe, effective, and cost-effective alternative. This study evaluated outpatient revisit costs associated with NIRF with indocyanine green vs isosulfan blue to explore the economic implications of adopting indocyanine green.

Materials and Methods

This retrospective, observational study analyzed data from adult female patients diagnosed with breast cancer undergoing sentinel lymph node mapping with isosulfan blue or NIRF with indocyanine green, indexed to outpatient hospital discharge between July 1, 2017, and August 31, 2022. Data were extracted from the US hospital-based PINC AI Healthcare Database. Patients were grouped based on the SLN mapping method utilized. Costs at 30, 60, and 90 days post procedure were assessed and adjusted to 2022 US dollars using the Medical Care Consumer Price Index.

Results

Among the 1,067,677 patients identified, 5.6% (n = 60,068) underwent SLN, with 11.8% (n = 7,076) meeting inclusion criteria. Outpatient revisit costs to the same hospital for the NIRF with indocyanine green cohort compared with the isosulfan blue cohort were $36 lower at 30 days ($3832 ± $5106 [median, $1,058] vs $3868 ± $4842 [median, $2020], P = NS), $845 lower at 60 days ($7,023 ± $9,360 [median, $3,112] vs $7868 ± $8658 [median, $4740], P <.05, statistically significant), and $774 lower at 90 days ($10,015 ± $13,215 [median, $5,445] vs $10,789 ± $12,166 [median, $5,879], P = NS). A hospital performing 100 SLN mapping procedures annually could save approximately $84,500 per year and $422,500 over 5 years in revisit costs with NIRF with indocyanine green, assuming $845 saved per case.

Conclusion

NIRF with indocyanine green for SLN mapping in breast cancer shows a trend toward cost savings compared with isosulfan blue, particularly at 60 days post procedure. These findings highlight the potential economic benefit of adopting NIRF with indocyanine green in clinical practice and warrant further research into its long-term cost-effectiveness and clinical outcomes.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content